Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EVO Evotec	$4.05 +6.0%	$4.11	$2.84 ▼ $5.64	$1.36B	1.66	90,481 shs	96,791 shs
NTLA Intellia Therapeutics	$12.78 -10.3%	$9.86	$5.90 ▼ $27.42	$1.48B	2.21	4.30 million shs	7.33 million shs
RCKT Rocket Pharmaceuticals	$3.21 -4.5%	$3.45	$2.19 ▼ $26.98	$358.80M	0.67	3.47 million shs	3.38 million shs
SRPT Sarepta Therapeutics	$12.89 -3.2%	$26.61	$10.41 ▼ $150.48	$1.31B	0.45	11.36 million shs	44.21 million shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EVO Evotec	+2.69%	-9.48%	+0.26%	-9.26%	-20.08%
NTLA Intellia Therapeutics	+5.56%	+19.06%	+54.28%	+74.08%	-46.18%
RCKT Rocket Pharmaceuticals	-0.30%	+17.48%	+27.76%	-54.78%	-86.49%
SRPT Sarepta Therapeutics	-2.13%	-27.53%	-29.41%	-78.43%	-90.98%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EVO Evotec	2.1005 of 5 stars	3.2	4.0	0.0	1.7	0.0	0.6
NTLA Intellia Therapeutics	4.5653 of 5 stars	4.3	1.0	4.7	3.2	2.5	0.6
RCKT Rocket Pharmaceuticals	4.8441 of 5 stars	4.2	3.0	4.7	1.7	4.2	1.3
SRPT Sarepta Therapeutics	4.7372 of 5 stars	4.1	2.0	4.2	2.2	1.7	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EVO Evotec	2.40	Hold	$5.93	46.50% Upside
NTLA Intellia Therapeutics	2.65	Moderate Buy	$33.37	161.10% Upside
RCKT Rocket Pharmaceuticals	2.41	Hold	$18.27	469.06% Upside
SRPT Sarepta Therapeutics	2.18	Hold	$51.42	298.89% Upside

Current Analyst Ratings Breakdown

Latest RCKT, EVO, SRPT, and NTLA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/24/2025	RCKT Rocket Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$17.00 ➝ $12.00
7/24/2025	RCKT Rocket Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
7/24/2025	SRPT Sarepta Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $35.00
7/24/2025	SRPT Sarepta Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$65.00 ➝ $48.00
7/23/2025	SRPT Sarepta Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Underperform
7/22/2025	SRPT Sarepta Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell ➝ Sell
7/22/2025	SRPT Sarepta Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sell ➝ Sell
7/22/2025	SRPT Sarepta Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Overweight ➝ Equal Weight	$32.00 ➝ $18.00
7/22/2025	SRPT Sarepta Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$18.00
7/21/2025	SRPT Sarepta Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform	$70.00 ➝ $50.00
7/21/2025	SRPT Sarepta Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral

(Data available from 7/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EVO Evotec	$862.40M	1.67	N/A	N/A	$2.91 per share	1.39
NTLA Intellia Therapeutics	$57.88M	22.87	N/A	N/A	$8.56 per share	1.49
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	$5.08 per share	N/A
SRPT Sarepta Therapeutics	$1.90B	0.67	$2.36 per share	5.47	$15.99 per share	0.81

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EVO Evotec	-$212.18M	N/A	0.00	N/A	N/A	-26.34%	-21.51%	-10.54%	8/13/2025 (Estimated)
NTLA Intellia Therapeutics	-$519.02M	-$5.23	N/A	N/A	N/A	-1,154.10%	-56.06%	-44.25%	8/14/2025 (Estimated)
RCKT Rocket Pharmaceuticals	-$258.75M	-$2.63	N/A	N/A	N/A	N/A	-64.92%	-56.13%	8/4/2025 (Estimated)
SRPT Sarepta Therapeutics	$235.24M	-$2.69	N/A	1.18	N/A	-11.12%	-14.88%	-5.12%	8/6/2025 (Estimated)

Latest RCKT, EVO, SRPT, and NTLA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	NTLA Intellia Therapeutics	-$1.03	N/A	N/A	N/A	$12.26 million	N/A
8/6/2025	Q2 2025	SRPT Sarepta Therapeutics	$0.89	N/A	N/A	N/A	$530.66 million	N/A
8/4/2025	Q2 2025	RCKT Rocket Pharmaceuticals	-$0.57	N/A	N/A	N/A	$4.36 million	N/A
5/13/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.58	-$0.56	+$0.02	N/A	N/A	N/A
5/8/2025	Q1 2025	NTLA Intellia Therapeutics	-$1.26	-$1.10	+$0.16	-$1.10	$11.39 million	$16.63 million
5/6/2025	Q1 2025	SRPT Sarepta Therapeutics	$2.20	-$3.42	-$5.62	-$4.60	$685.75 million	$744.86 million
5/5/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.59	-$0.56	+$0.03	-$0.56	$0.80 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EVO Evotec	N/A	N/A	N/A	N/A	N/A
NTLA Intellia Therapeutics	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SRPT Sarepta Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EVO Evotec	0.46	2.03	1.93
NTLA Intellia Therapeutics	N/A	4.90	4.90
RCKT Rocket Pharmaceuticals	0.05	9.19	9.19
SRPT Sarepta Therapeutics	1.00	4.02	2.46

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EVO Evotec	5.81%
NTLA Intellia Therapeutics	88.77%
RCKT Rocket Pharmaceuticals	98.39%
SRPT Sarepta Therapeutics	86.68%

Insider Ownership

Company	Insider Ownership
EVO Evotec	1.00%
NTLA Intellia Therapeutics	3.10%
RCKT Rocket Pharmaceuticals	24.76%
SRPT Sarepta Therapeutics	7.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EVO Evotec	4,827	355.11 million	351.56 million	Not Optionable
NTLA Intellia Therapeutics	600	103.58 million	100.37 million	Optionable
RCKT Rocket Pharmaceuticals	240	106.79 million	80.35 million	Optionable
SRPT Sarepta Therapeutics	1,372	98.28 million	90.71 million	Optionable

RCKT, EVO, SRPT, and NTLA Headlines

Recent News About These Companies

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Hims & Hers and Sarepta and Encourages Investors to Contact the Firm

4 hours ago | globenewswire.com

Elevidys Halt Sparks Analyst Downgrades—Sarepta Races To Revise Label

5 hours ago | benzinga.com

Sarepta's licensing partner Arrowhead expects near-term payments despite setbacks

5 hours ago | msn.com

Sarepta stock faces multiple downgrades and questions of solvency amid Elevidys pause

5 hours ago | aol.comA

4SRPT : Sarepta Therapeutics's Options Frenzy: What You Need to Know

5 hours ago | benzinga.com

The Hits Keep Coming For Sarepta. Why Its Latest Setback Creates A 'Dangerous Precedent' For Gene Therapies.

5 hours ago | msn.com

Sarepta drops as report suggests FDA needs new trials for Elevidys

5 hours ago | msn.com

Investors in Sarepta Therapeutics, Inc. Should Contact The Gross Law Firm Before August 25, 2025 to Discuss Your Rights – SRPT

July 24 at 4:00 PM | globenewswire.com

Sarepta Therapeutics (SRPT): “They Should Be Prosecuted,” Says Jim Cramer

July 24 at 12:25 PM | insidermonkey.com

Sarepta Therapeutics stock tumbles on concern about FDA study requirements

July 24 at 12:25 PM | investing.com

Positive Long-Term Outlook for Sarepta Therapeutics Amid Regulatory Challenges

July 24 at 11:11 AM | tipranks.com

This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday

July 24 at 9:42 AM | benzinga.com

The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Sarepta Therapeutics, Inc.(SRPT) Shareholders

July 24 at 8:45 AM | prnewswire.com

SRPT STOCK NEWS: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is Facing Securities Fraud Allegations – Investors with Losses are Notified to Contact BFA Law by August 25 Deadline

July 24 at 8:06 AM | globenewswire.com

Citi Initiates Coverage on Sarepta Therapeutics (SRPT) with "Sell" Rating | SRPT ...

July 24 at 7:07 AM | gurufocus.com

Sarepta Therapeutics (SRPT) Tanks 36% After 3rd Patient Death, SRPT Securities Class Action Pending; Investors With Substantial Losses And Persons With Knowledge Encouraged To Contact Hagens Berman

July 23 at 6:07 PM | globenewswire.com

SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit

July 23 at 4:08 PM | prnewswire.com

Sarepta Therapeutics (SRPT) Faces Downgrade Amid Elevidys Concerns

July 23 at 2:58 PM | gurufocus.com

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics

July 23 at 11:53 AM | prnewswire.com

Bank of America Reiterates "Underperform" Rating for Sarepta Therapeutics (NASDAQ:SRPT)

July 23 at 8:10 AM | marketbeat.com

Sarepta's licensing patner Arrowhead expects near-term payments despite setbacks

July 23 at 8:05 AM | reuters.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

The Meteoric Rise of Rocket Lab: A Space Stock to Watch
By Ryan Hasson | July 11, 2025
View The Meteoric Rise of Rocket Lab: A Space Stock to Watch
3 Analysts Set $600 Target Ahead of Microsoft Earnings
By Chris Markoch | July 15, 2025
View 3 Analysts Set $600 Target Ahead of Microsoft Earnings
Aeva & Mobileye: LiDAR Stocks Powering the Autonomous Revolution
By Dan Schmidt | July 2, 2025
View Aeva & Mobileye: LiDAR Stocks Powering the Autonomous Revolution
Investors Are Waking Up to Arista Networks—Here’s the Scoop
By Jeffrey Neal Johnson | June 26, 2025
View Investors Are Waking Up to Arista Networks—Here’s the Scoop
Kinder Morgan: At the Hotspot of the Natural Gas Revolution
By Thomas Hughes | July 21, 2025
View Kinder Morgan: At the Hotspot of the Natural Gas Revolution

RCKT, EVO, SRPT, and NTLA Company Descriptions

Evotec NASDAQ:EVO

$4.05 +0.23 (+6.02%)

Closing price 04:00 PM Eastern

Extended Trading

$4.07 +0.02 (+0.59%)

As of 07:55 PM Eastern

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc.; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic, as well as research collaboration with Pfizer for metabolic and infectious diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Intellia Therapeutics NASDAQ:NTLA

$12.78 -1.46 (-10.25%)

Closing price 04:00 PM Eastern

Extended Trading

$12.81 +0.03 (+0.23%)

As of 07:58 PM Eastern

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Rocket Pharmaceuticals NASDAQ:RCKT

$3.21 -0.15 (-4.46%)

Closing price 04:00 PM Eastern

Extended Trading

$3.20 0.00 (-0.16%)

As of 07:58 PM Eastern

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

Sarepta Therapeutics NASDAQ:SRPT

$12.89 -0.43 (-3.23%)

Closing price 03:59 PM Eastern

Extended Trading

$12.52 -0.37 (-2.83%)

As of 08:00 PM Eastern

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time